How would you approach a BRAF negative metastatic melanoma patient on immune checkpoint inhibitor therapy with enlarging, symptomatic brain lesions that had previously been treated with SRS?

Topics: Radiation Oncology • Melanoma/Skin Cancer • Medical Oncology • Immunotherapy

If on pembrolizumab or nivolumab, when would you escalate to ipilimumab/nivolumab?

Answer from: Medical Oncologist at Academic Institution

Depending on the PS and medical history of the patient, would recommend moving them to ipi (3 mg/kg)/nivo (1 mg/kg) as soon as possible. - Brent Hanks

Comments

Medical Oncologist at Hematology Oncology Medical Group of Orange County
Could it be a radiation necrosis? If this is the o...

Medical Oncologist at Florida Cancer Specialists and Research Institute
Would single agent ipi be ok given that the progre...

Related Questions